Empyema caused by MRSA ST398 with Atypical Resistance Profile, Spain by Lozano, Carmen et al.
LETTERS
Empyema caused 
by MRSA ST398 
with Atypical 
Resistance 
Proﬁ  le, Spain
To the Editor: We report a case of 
empyema caused by methicillin-resis-
tant  Staphylococcus aureus (MRSA) 
sequence type ST398 in a 79-year-old 
man in Spain who had severe chronic 
obstructive pulmonary disease. In 
2009, the patient was hospitalized 
in the intensive care unit because of 
decompensation of his chronic ob-
structive pulmonary disease, profound 
iliofemoral venous thrombosis, right 
pneumothorax, and lung carcinoma. 
Thoracic drainage, support measures, 
and intravenous levoﬂ  oxacin  were 
initiated, but no clinical improvement 
was seen. Purulent exudates from the 
thoracic drainage tube and of a trache-
al aspirate were cultured. MRSA was 
isolated from both samples and from a 
nasal swab. Antimicrobial drug thera-
py was changed from levoﬂ  oxacin to 
intravenous linezolid, but the patient’s 
clinical situation rapidly worsened, 
and he died of multiorgan failure.
The 3 MRSA isolates were typed 
(multilocus sequence typing-, spa-, 
staphylococcal cassette chromosome 
[SCC]  mec-, and agr-typing, in ad-
dition to pulsed-ﬁ  eld gel electropho-
resis [PFGE]), likewise, the antimi-
crobial drug–resistance phenotypes 
and genotypes, and virulence genes 
were determined (1,2). All 3 MRSA 
isolates were typed as sequence type 
(ST) 398, spa-type t011, SCCmecV, 
and agrI. The 3 isolates had the same 
resistance phenotype, including to 
β-lactams, tetracycline, clindamycin 
(but not erythromycin), ciproﬂ  oxa-
cin, and levoﬂ  oxacin. We conﬁ  rmed 
the presence of mecA,  tetM,  tetK, 
and  vga(A) genes by PCR and se-
quencing; however, PCRs for lnu(A), 
lnu(B),  lnu(C),  lnu(D),  cfr, vga(C), 
lsa(B), and tetL genes were negative. 
Primers used for detection of vga(A) 
gene were F-5′-GAAACTCTTATTC
GAACYATTCTAGC-3′ and R-5′- 
GGTTCAATACTCAATCGACT-
GAG-3′. Speciﬁ  c amino acid changes 
in the quinolone-determining region 
of GyrA and ParC proteins (S84L and 
S80F, respectively) were detected by 
PCR and sequencing (1). All 3 MRSA 
isolates were negative by PCR for the 
Panton-Valentine leukocidin, toxic 
shock syndrome toxin 1, and exfolia-
tive toxins A and B.
The patient lived with his wife 
and 2 sons near a pig farm. Both sons 
worked on the farm; the patient, but 
not his wife, helped sporadically on the 
farm. Nasal samples from the 3 family 
members indicated MRSA carriage in 
1 son but not in the other son or the pa-
tient’s wife. The characteristics of the 
nasal MRSA strain recovered from the 
son were identical to those previously 
detected in MRSA strains from the pa-
tient (Table). In addition, nasal swabs 
from 18 pigs on the farm were ran-
domly taken, and MRSA isolates were 
detected in 9 (50%) pigs; 1 MRSA 
isolate per animal was further charac-
terized. Eight isolates were typed as 
ST398/t011/SCCmecV/agrI, and the 
remaining one as ST398/t1451/SC-
CmecV/agrI. All animal isolates had 
the same resistance phenotype and 
genotype as the MRSA isolates from 
the patient and son. None harbored the 
studied virulence factors (Table). All 
isolates had an unusual clindamycin-
resistance/erythromycin-susceptibility 
phenotype and harbored the vga(A) 
gene. 
We analyzed all MRSA isolates 
of human and animal origins by ApaI-
PFGE (2) and compared patterns as 
previously recommended (3). Only 
1 pulsotype (A) and 3 closely related 
subtypes were identiﬁ  ed  (A1,  A2, 
and A3). One MRSA isolate obtained 
from pleural ﬂ  uid of the patient, 2 iso-
lates from nasal swabs (patient and 
son), and most isolates from animals 
showed the same PFGE pulsotype and 
subtype (A1). Alternatively, 1 MRSA 
isolate from bronchial aspirate of the 
patient and 2 isolates from animals 
showed closely related patterns (sub-
types A2 and A3).
Other studies have suggested clon-
al spread and transmission of MRSA 
ST398 between pigs and persons who 
work with them (4,5). This microor-
ganism has been generally associated 
with skin and soft tissue infections 
in humans (6). Nevertheless, severe 
infections by ST398 also have been 
sporadically described, and the report 
of 7 pneumonia cases associated with 
mechanical ventilation in central Eu-
rope is relevant (7). In general, ST398 
isolates have fewer virulence factors 
than do other clones of MRSA (2); 
nonetheless, human infections from 
Panton-Valentine leukocidin–positive 
ST398 isolates have been reported (8). 
The immunocompromised status of 
patients in intensive care units could 
favor dissemination of ST398 in this 
environment.
MRSA ST398 implicated in the 
described empyema was resistant to 
the ﬁ  rst-line antimicrobial agent used 
for treatment (levoﬂ  oxacin,  MIC  4 
mg/L) that was associated with amino 
acid changes in GyrA and ParC pro-
teins, which could have accelerated the 
deteriorating evolution of the patient’s 
respiratory infection. The atypical 
clindamycin-resistance/erythromycin-
susceptibility phenotype detected in 
our human and animal MRSA strains 
is infrequently detected in clinical 
MRSA isolates from humans. Nev-
ertheless, this phenotype might be 
emerging among livestock MRSA 
isolates, as we and others (9,10) have 
observed. The vga(A) gene detected in 
these isolates could be responsible for 
this resistant phenotype, as has been 
recently reported by others (10).
In conclusion, we report potential 
pig-to-human transmission of MRSA 
ST398. MRSA ST398 can be associ-
ated with severe respiratory pathol-
ogy in immunocompromised patients, 
and these microorganisms could also 
be resistant to other ﬁ  rst-line antimi-
crobial agents, such as ﬂ  uoroquino-
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lones, used to treat these infections. 
Moreover, the unusual clindamycin-
resistance/erythromycin-susceptibility 
phenotype might be a key marker (in 
addition to tetracycline resistance) for 
the possible presence of livestock-as-
sociated MRSA.
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Table. Characteristics of methicillin-resistant Staphylococcus aureus strains recovered from humans and animals, Spain, 2009* 
Strain Origin 
SCCmec
type 
MLST/spa
type  agr PFGE 
Antimicrobial resistance 
phenotype 
Resistance genes 
detected 
Amino acid 
change
GrlA GyrA 
C2355 Patient,   
pleural fluid 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2354 Patient,
bronchial aspirate 
V ST398/t011 I A2 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2634 Patient,
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2664 Son,
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2669 Pig  1, 
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2670 Pig  2, 
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2694 Pig  3, 
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2695 Pig  4, 
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2697 Pig  5, 
nasal swab 
V ST398/t011 I A3 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2698 Pig  6, 
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2700 Pig  7, 
nasal swab 
V ST398/t011 I A3 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2704 Pig  8, 
nasal swab 
V ST398/t011 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
C2706 Pig  9, 
nasal swab 
V ST398/t1451 I A1 OXA-CLI-TET-CIP-LEV  mecA, tetK, tetM,
vga(A) 
S80F S84L
*All strains were susceptible to fusidic acid, fosfomycin, gentamicin, tobramycin, mupirocin, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin, 
quinupristin/dalfopristin, and tigecycline. SCC, staphylococcal cassette chromosome; MLST, multilocus sequence typing; PFGE, pulsed-field gel 
electrophoresis; ST, sequence type; OXA, oxacillin; CLI, clindamycin; TET, tetracycline; CIP, ciprofloxacin; LEV, levofloxacin.LETTERS
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Intensive Care Unit 
Admission for 
Pandemic (H1N1) 
2009, Reunion 
Island, 2009
To the Editor: We report results 
of the prospective surveillance system 
established in the largest intensive 
care unit (ICU) of Reunion Island (25 
beds). This system covers 500,000 
residents (62% of the total population) 
and monitors the daily status of patients 
>17 years of age who had a positive 
reverse transcription–PCR (RT-PCR) 
for pandemic (H1N1) 2009 virus. Re-
union Island is a French overseas terri-
tory in the Southern Hemisphere, with 
health care facilities similar to those 
of mainland France. Patients were fol-
lowed up until discharge from the ICU 
or death. Data were collected during 
July 15–September 30, 2009.
Of 148 patients with conﬁ  rmed 
pandemic (H1N1) 2009 infection 
admitted to the hospital, 13 (9%) pa-
tients (8 female) were admitted to the 
ICU. These corresponded to 7% of all 
187 patients admitted to the ICU dur-
ing the same period. Median age was 
39.4 (±19) years (range 17–69 years). 
Ten patients were admitted for respi-
ratory failure related to viral pneu-
monitis, 1 for pulmonary edema with 
severe chronic coronary insufﬁ  ciency, 
1 for congenital adrenal insufﬁ  ciency 
with reversible multiple organ failure, 
and 1 for status epilepticus. Eleven 
(85%) patients had underlying concur-
rent medical conditions: 3 were over-
weight (body mass indexes 38, 32, and 
29.3 kg/m2); 1 was pregnant and had 
asthma.
Four (31%) patients died. One 
was a 28-year-old woman with ce-
rebral motor inﬁ   rmity and severe 
chronic restrictive respiratory failure. 
An 18-year-old woman with aplasia 
after receipt of an allograft for Hodg-
kin lymphoma died of cerebral hemor-
rhage while receiving extracorporeal 
membrane oxygenation. A 52-year-
old man admitted for pulmonary ede-
ma with severe coronary insufﬁ  ciency 
died of multiple organ failure. A 33-
year-old man with no known concur-
rent medical conditions died of acute 
respiratory distress syndrome. Time 
from ICU admission to death ranged 
from 15 to 85 days (mean 36.5 ± 32 
days). Mean age of patients who died 
was 32.5 ± 14.3 years.
Chest radiographic ﬁ  ndings were 
abnormal for all patients except 1, who 
was admitted for fever and convul-
sions (Huntington chorea). Bilateral 
pulmonary embolism was conﬁ  rmed 
in an obese patient who survived.
Mean time between onset of clini-
cal signs and ICU admission was 6.9 ± 
3.2 days. Mean time between admis-
sion to ICU with diagnosis conﬁ  rmed 
by RT-PCR and initiation of antivi-
ral treatment was 1.8 ± 1.7 days and 
between illness onset and initiation 
of antiviral treatment, 8.8 ± 3 days 
(range 4–16 days). Mean length of 
ICU stay was 26.3 ± 29.3 days. Pa-
tients remained in the ICU for a total 
of 201 bed-days (402 per million resi-
dents). The maximum daily occupan-
cy of the ICU was 10 beds per million 
residents.
Five patients received steroids 
for severe hypotension or asthma-like 
clinical illness. Severe hypotension 
developed in 5 patients, and they re-
ceived vasopressors. No patient re-
ceived intravenous immunoglobulins. 
Ten (77%) patients required mechani-
cal ventilation for a median of 11.5 ± 
12.2 days. One patient required high-
frequency ventilation, 3 required ex-
tracorporeal membrane oxygenation, 
and 1 required hemodialysis. Multiple 
organ failure developed in 3. All pa-
tients were empirically given anti-
bacterial drugs. Secondary infections 
were either documented or strongly 
suspected for 5 patients.
All patients received oral oselta-
mivir beginning 4–16 days after ill-
ness onset and continuing for 2–17 
days (mean 7.2 ± 4.3). Zanamivir 
was administered 1 time by inhala-
tion through the ventilator. Viral loads 
in respiratory specimens ranged from 
4 × 103 to 6.9 × 107 copies/mL (mean 
1.4 × 105). Two patients excreted virus 
in their bronchoalveolar lavage speci-
mens for a prolonged time (14 days).
The most prominent biological 
ﬁ  ndings were elevated serum levels of 
procalcitonin, C-reactive protein, as-
partate aminotransferase, alanine ami-
notransferase, lactate dehydrogenase, 
and creatine kinase. Eight patients had 
lymphopenia (<1,200 cells/mm3).
Our ﬁ  ndings are consistent with 
ﬁ  ndings of other studies of severe or 
fatal viral pneumonia in younger pa-
tients than are usually affected in a 
normal inﬂ   uenza season (1–4), par-
ticularly in patients with concurrent 
medical conditions. In our study, the 3 
overweight patients survived. Obesity 
is associated with increased severity of 
illness, but not always with death, in 
critically ill patients (5). We conﬁ  rm 
that previously healthy young persons 
can die of pandemic (H1N1) 2009, 
although at a much lower rate than 
those infected in the initial outbreaks 
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